Therapeutic effect and psychological impact of aspirin plus edaravone on patients with cerebral infarction

IF 3.9 4区医学 Q1 PSYCHIATRY

World Journal of Psychiatry Pub Date : 2024-05-19 DOI:10.5498/wjp.v14.i5.644

Tian-Shu Wang, Li-Jun Jing

{"title":"Therapeutic effect and psychological impact of aspirin plus edaravone on patients with cerebral infarction","authors":"Tian-Shu Wang, Li-Jun Jing","doi":"10.5498/wjp.v14.i5.644","DOIUrl":null,"url":null,"abstract":"BACKGROUND\n Cerebral infarction (CI) is characterized by a high prevalence, disability, and mortality. Timely or improper treatment greatly affects patient prognosis.\n AIM\n To explore the drug efficacy of aspirin plus edaravone and to explore their effect on quality of life (QOL), anxiety and depression in CI patients.\n METHODS\n We retrospectively analyzed the records of 124 CI patients treated between June 2019 and February 2021 who were assigned to an observation group (OG) (combination therapy of aspirin and edaravone, 65 patients) or a control group (CG) (aspirin monotherapy, 59 patients). The therapeutic effects, pre- and posttreatment National Institutes of Health Stroke Scale (NIHSS) scores, activities of daily living, degree of cognitive impairment, protein levels of glial fibrillary acidic protein (GFAP), neuron-specific enolase (NSE) and S-100B, occurrence of adverse reactions, and serum high-sensitivity C-reactive protein (hs-CRP), interleukin (IL)-6 and tumor necrosis factor (TNF)-α were evaluated, detected and compared between the two groups. Finally, posttreatment QOL, anxiety, and depression were assessed by the Medical Outcomes Study 36- Item Short Form Health Survey Scale, Self-rating Depression Scale (SDS), and Self-rating Anxiety Scale (SAS), respectively.\n RESULTS\n Compared with the CG, the OG had markedly better therapeutic effects, greater improvements in activities of daily living, and better alleviation in cognitive dysfunction after treatment, as well as lower posttreatment NIHSS scores and serum NSE, GFAP, S-100B, hs-CRP, IL-6, and TNF-α levels; the OG was similar to the CG in terms of adverse reactions but was better than the CG in terms of posttreatment QOL; and the OG also had lower SDS and SAS scores than the CG after treatment.\n CONCLUSION\n Aspirin plus edaravone had a good curative effect on CI. It can reverse cranial nerve damage in patients, improve neurological function and prognosis, and alleviate inflammation, anxiety, and depression; thus, it is considered safe and worthy of clinical application.","PeriodicalId":23896,"journal":{"name":"World Journal of Psychiatry","volume":null,"pages":null},"PeriodicalIF":3.9000,"publicationDate":"2024-05-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"World Journal of Psychiatry","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.5498/wjp.v14.i5.644","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"PSYCHIATRY","Score":null,"Total":0}

引用次数: 0

Abstract

BACKGROUND Cerebral infarction (CI) is characterized by a high prevalence, disability, and mortality. Timely or improper treatment greatly affects patient prognosis. AIM To explore the drug efficacy of aspirin plus edaravone and to explore their effect on quality of life (QOL), anxiety and depression in CI patients. METHODS We retrospectively analyzed the records of 124 CI patients treated between June 2019 and February 2021 who were assigned to an observation group (OG) (combination therapy of aspirin and edaravone, 65 patients) or a control group (CG) (aspirin monotherapy, 59 patients). The therapeutic effects, pre- and posttreatment National Institutes of Health Stroke Scale (NIHSS) scores, activities of daily living, degree of cognitive impairment, protein levels of glial fibrillary acidic protein (GFAP), neuron-specific enolase (NSE) and S-100B, occurrence of adverse reactions, and serum high-sensitivity C-reactive protein (hs-CRP), interleukin (IL)-6 and tumor necrosis factor (TNF)-α were evaluated, detected and compared between the two groups. Finally, posttreatment QOL, anxiety, and depression were assessed by the Medical Outcomes Study 36- Item Short Form Health Survey Scale, Self-rating Depression Scale (SDS), and Self-rating Anxiety Scale (SAS), respectively. RESULTS Compared with the CG, the OG had markedly better therapeutic effects, greater improvements in activities of daily living, and better alleviation in cognitive dysfunction after treatment, as well as lower posttreatment NIHSS scores and serum NSE, GFAP, S-100B, hs-CRP, IL-6, and TNF-α levels; the OG was similar to the CG in terms of adverse reactions but was better than the CG in terms of posttreatment QOL; and the OG also had lower SDS and SAS scores than the CG after treatment. CONCLUSION Aspirin plus edaravone had a good curative effect on CI. It can reverse cranial nerve damage in patients, improve neurological function and prognosis, and alleviate inflammation, anxiety, and depression; thus, it is considered safe and worthy of clinical application.

查看原文本刊更多论文

阿司匹林加依达拉奉对脑梗塞患者的治疗效果和心理影响

背景脑梗塞（CI）具有发病率高、致残率高和死亡率高的特点。治疗是否及时或不当对患者的预后有很大影响。目的探讨阿司匹林联合依达拉奉的药物疗效，并探讨其对 CI 患者生活质量（QOL）、焦虑和抑郁的影响。方法我们回顾性分析了2019年6月至2021年2月期间接受治疗的124例CI患者的病历，这些患者被分配到观察组（OG）（阿司匹林和依达拉奉联合治疗，65例患者）或对照组（CG）（阿司匹林单药治疗，59例患者）。对两组患者的治疗效果、治疗前后美国国立卫生研究院卒中量表（NIHSS）评分、日常生活能力、认知障碍程度、神经胶质纤维酸性蛋白（GFAP）、神经元特异性烯醇化酶（NSE）和 S-100B 蛋白水平、不良反应发生率、血清高敏 C 反应蛋白（hs-CRP）、白细胞介素（IL）-6 和肿瘤坏死因子（TNF）-α 进行评估、检测和比较。最后，分别采用医学结果研究 36 项简式健康调查量表、抑郁自评量表（SDS）和焦虑自评量表（SAS）对治疗后的 QOL、焦虑和抑郁进行评估。结果与CG相比，OG治疗后的疗效明显更好，日常生活活动得到更大改善，认知功能障碍得到更好缓解，治疗后NIHSS评分和血清NSE、GFAP、S-100B、hs-CRP、IL-6和TNF-α水平更低；OG在不良反应方面与CG相似，但在治疗后QOL方面优于CG；OG治疗后的SDS和SAS评分也低于CG。结论阿司匹林联合依达拉奉对 CI 有良好的疗效。它可以逆转患者的颅神经损伤，改善神经功能和预后，缓解炎症、焦虑和抑郁，因此被认为是安全的，值得临床应用。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

World Journal of Psychiatry PSYCHIATRY-

自引率

6.50%

发文量

110

期刊介绍： The World Journal of Psychiatry (WJP) is a high-quality, peer reviewed, open-access journal. The primary task of WJP is to rapidly publish high-quality original articles, reviews, editorials, and case reports in the field of psychiatry. In order to promote productive academic communication, the peer review process for the WJP is transparent; to this end, all published manuscripts are accompanied by the anonymized reviewers’ comments as well as the authors’ responses. The primary aims of the WJP are to improve diagnostic, therapeutic and preventive modalities and the skills of clinicians and to guide clinical practice in psychiatry.